Member Info for TorquayFan

From the Linkedin note from WTP earlier - "Joseph’s presentation, ‘A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab induces functional CD4 and CD8 T cell responses in patients with advanced unresectable melanoma, will showcase new data from our Phase 2 SCOPE study of lead Immunobody® .

Poster session B is tomorrow 25th. I'm not sure what the earlier discussion concluded about the 'new' in 'showcase new data' actually meant i.e. 'new' to the Conference circuit or 'new new' data.

Just pondering there might be an RNS either tomorrow or Wednesday, if 'new new' is what those words meant. Go Joseph !!

EE thanks for 12.47 - fair comment. I agree MBU.

However, whilst many contend that, the market 'is always right', I think it fair to say that in view of the "huge scientific accomplishments" of Prof. Lindy and Team Scancell, the current SP is not representative of the value here. Just 8.75 pence is freakishly low, (IMHO), and getting past 11.7 pence should, FGS, be a breeze in a shortish timescale.

I remain of the view that for CEO to have options 10% greater than the CSO, for his few years work, considering the CSO's lifetime contribution here, is excessively generous.

But we are where we are. Let's hope the CEO proves to be worth it ?

GG thanks for asking that question.

RW ? Anyone ?

Yes WTP, an intriguing suggestion by EE 07.26 - one lives in hopes!

BUT, whilst wishing the CEO M. L'Huillier the very best of fortunes (along with us) in the future, I am, after being stuck here for 14 years now and underwater for nearly all that time, somewhat amazed at the generosity of his share options deal, pre-agreed or not.

I don't begrudge a single one of Prof. Lindy's options of course. But for our newbie CEO to be so handsomely rewarded with a lofty 3% of the Company, for what will be, hopefully, a few years work from the Guy, is way over the top IMO.

Let's hope you are worth it Phil !!!

‘Patients in this long-term study have been followed for seven years now, and the results are fundamentally changing how we think about melanoma that has spread to the brain,’ said Professor Grant McArthur AO who heads Peter Mac’s Molecular Oncology Laboratory and is co-senior author on the study.

‘A situation that was considered terminal and with very limited treatment options now appears to be curable, based on these new data. More broadly, this continues the trend we’ve seen over recent decades as new immunotherapy-based approaches emerge and change advanced melanoma into not only a manageable disease but a curable disease for some patients,’ he said.

Australia has the highest melanoma rates in the world with one person diagnosed with the disease every 30 minutes and one person dying every 6 hours.

‘We have previously shown that with immunotherapy, metastatic melanoma is no longer a death sentence,’ said Associate Professor Alex Menzies from Melanoma Institute Australia and co-senior author on the study. ‘This is now the case even for patients with brain metastases, who used to have the worst of the worst prognosis. Results here will not only transform melanoma care but also lead to improvements across the cancer spectrum,’ he said. ""

Thanks again Burble

Re. the 'lay' link in 07.03 :-

""From just 16 weeks’ survival to long term disease control – new data confirms life-saving impact of breakthrough melanoma treatment.

Newly released long-term data from a groundbreaking clinical trial for advanced melanoma patients whose disease had spread to their brain has proven that long-term disease control has been achieved for over 50% of patients given combination immunotherapy as first line treatment.

The impressive 7-year follow up results from the ABC clinical trial were published today in the high impact journal Lancet Oncology.

Brain metastases are present in 30-40% of patients at diagnosis with Stage 4 (advanced) melanoma. In the past, these patients only survived for around 16 weeks.

The ABC trial was the first to demonstrate that these advanced melanoma patients could be successfully treated with combination immunotherapy using nivolumab and ipilimumab. So impressive were early survival rates from the trial, released in 2018, clinical practice changed virtually overnight.

‘The 7-year follow-up results released today show overall survival of 48% of patients on combination immunotherapy, with the survival rate increasing to 51% in patients given the treatment upfront. This proves we have achieved long-term disease control in this group of advanced melanoma patients,’ said Professor Georgina Long AO, Medical Director of Melanoma Institute Australia and lead author of the study.

‘We are now confident these patients are cured, a term not used lightly in cancer. This combination immunotherapy should now become standard of care for melanoma patients with brain metastasis,’ she said.

The randomized, phase 2 study was conducted at four sites in Australia – Melanoma Institute Australia, Princess Alexandra Hospital, Royal Adelaide Hospital and Peter MacCallum Cancer Centre.

Between 2014 and 2017, 79 patients were enrolled in the ABC trial, with 36 given combination checkpoint inhibitor immunotherapy (anti-PD-1 plus anti-CTLA-4) and 43 given single agent immunotherapy (nivolumab).

Initial results released in 2018 showed a 46% response rate for those patients given the combination immunotherapy, versus just 20% response rate for those on single agent immunotherapy.

The 7-year results, released today, show progression free survival rate was 42% with ipilimumab plus nivolumab, compared to 15% with nivolumab alone. Overall survival was 48% and 26% respectively.

In patients treated upfront, or as first line treatment, 7-year progression free survival rate was 47% with the combination immunotherapy and 14% with the single agent, with overall survival 51% and 29% respectively.

This is the longest follow-up ever for melanoma patients with active brain metastases. Results show that, if treated with this combination immunotherapy upfront, these patients can have similar outcomes to those melanoma patients without active brain disease.

(cont'd)

Thanks Burble - a further opportunity for Scancell, to enhance this amazing CI combo for these desperate Patients, with SCIB1/iSCIB1+ wizardry? Prof. Georgia Long - all power to her elbow as they say. Amazing . . .

WTP - yes I wondered about that. But maybe 'new data' refers to the last 'public' presentation. Who knows? I don't. I hope it's 'new' too, but we'll see. ATB

Violin - yes I get it. But we have to wait for the trials and the data. The CEO's deal is unknown of course, but he knows the game - I'm sure of that. Meantime, find something else to do. Chin up! ATB

Sorry Violin - you are clutching at straws !

The trials proceed - data is good.

When the time comes . . . . ATB

Chester - you put your point fairly but as a reminder, this is from EE 04.04 earlier - "at some point a deal will become do-able with GenMab and possibly others".

Genmab are to the forefront of discussion here for obvious reasons, but the central point holds, that is, we just don't know what discussions might be going on in the background - or with whom they are being held. Or when, someone might make a move.

Roll on the day !!

Thanks for your excellent 04.11 EE and I particularly concur with para 4.

We just don't know what discussions ARE going on and as I have posted many times over the years, "she'll be coming 'round the mountain when she comes". In the event of Genmab making a move, I would expect they'd look at a buyout of the Glymab platform, maybe with AvidMab too, rather than Scancell itself.

Now with 2x $600 million already on the punt - that might be tasty money !

Ruck your 60p minimum is a reasonable punt in the context you present it - but roughly, that represents the successful conclusion of just one of the GenMab deals in hand. That's to ignore SC129, SCIB1, iSCIB1+, Moditope and the power of Scancell to help BigPharma with their patent cliffs.

Despite my age, I'd start doing cartwheels as 60p but I think there is a good case that there is much more than 60p to look forward to.

But we'll see. GLA

Thanks EE.

Thanks Cleaner. I'm not sure who Elisa Marelli is in the Scancell hierarchy, but anyway, good to see the publicity. Perhaps we'll learn more after NextGen Biomed.

EE you can be reassured that Dentists in Thailand are generally quite excellent and also, available at short notice. Good luck.

So "90% of the contributors to this BB" . . . "struggle with . . . social skills, emotional intelligence, and interpersonal relationships". I guess that you see yourself, as being in the 10%? As of course, do I.

But Ruck seems to imply it was a 'joke' now. Enough for me.

A trip to Laem Sing, a waterside restaurant, 'Au Samet Dang' beckons.

No Ruck. I didn't think your 09.47 necessarily applied to me, but anyway, it was insulting to an unspecified 90% of Posters. Your 'clever dick' tendency on display. If you think 09.47 was funny you need a transplant somewhere - it was grossly offensive and gave no clue you might be 'jesting'.

As for the 'sense of humour' implication, really! How would I have survived as a Scancell investor, for 14 years without one?

With a few exceptions, we are all doing our best on the BB and I appreciate very much the efforts that more than 90% (IMO), consistently put in.

I think it's obvious but 14.28 was for you Ruck.

I find your 09.47 (and your 5 recs), grossly offensive, (particularly, living in a glasshouse as you do). With a few exceptions (IMHO), we are all doing our best on the BB.

Cleaner- thanks for your 11.15 but, contribute to a discussion ?

Your heads up is a good, good, good vibration, but further discussion would be difficult really, as atm we know very little about what might be going on.

But thanks, ATB